Novartis: leukemia drug Gleevec China's most expensive
It is predicted that the Asia-Pacific (APAC) region with type 2 diabetes drug market in 2020 will grow to $ 10.5 billion. Business intelligence provider GBI Research predicts that the market will grow $ 4 billion in 2013 for $ 6.5 billion, based on the number of people in these areas because of the growth in diabetic patients, and patients get the drugs selegilina will increase.
This forecast representative compound annual growth rate of 7.1% (CAGR), reported that four major APAC countries, China, India, Japan and Australia, China will have the fastest expansion since its CAGR from 2013 will reach 11.1 %. This figure is likely to be affected by several new types of type 2 diabetes drugs listed, they will complement the existing standard therapy of metformin and sulfonylurea.
New types of drugs, including GLP-1 agonists, such as Novo Nordisk's liraglutide, SGLT2 inhibitors, such as AstraZeneca Dagelieting, and DPP-4 inhibitors, such as Boehringer Ingelheim Lee Lali Ting.
GBI Research analyst Singh commented: "In the framework of the overall treatment of type 2 diabetes, although metformin is expected to maintain its dominant position, it is expected that the listing of promising research line drugs may also contribute to market expansion, which deprenyl includes several new the mechanism of drug action. "
According to Singh, said that these new products will have to prove they are cheap compared with metformin and sulphonylureas flavopiridol deserve to be higher prices. "If these late-stage development line drugs are not consistently show strong efficacy throughout the three trials, or is found to have a slight possibility of serious adverse events, such as cancer, that their commercial potential will be severely reduced."
This forecast representative compound annual growth rate of 7.1% (CAGR), reported that four major APAC countries, China, India, Japan and Australia, China will have the fastest expansion since its CAGR from 2013 will reach 11.1 %. This figure is likely to be affected by several new types of type 2 diabetes drugs listed, they will complement the existing standard therapy of metformin and sulfonylurea.
New types of drugs, including GLP-1 agonists, such as Novo Nordisk's liraglutide, SGLT2 inhibitors, such as AstraZeneca Dagelieting, and DPP-4 inhibitors, such as Boehringer Ingelheim Lee Lali Ting.
GBI Research analyst Singh commented: "In the framework of the overall treatment of type 2 diabetes, although metformin is expected to maintain its dominant position, it is expected that the listing of promising research line drugs may also contribute to market expansion, which deprenyl includes several new the mechanism of drug action. "
According to Singh, said that these new products will have to prove they are cheap compared with metformin and sulphonylureas flavopiridol deserve to be higher prices. "If these late-stage development line drugs are not consistently show strong efficacy throughout the three trials, or is found to have a slight possibility of serious adverse events, such as cancer, that their commercial potential will be severely reduced."
评论
发表评论